Korea Research Institute of Bioscience and Biotechnology

Insect Biotech Co., Ltd.

Inssect Biotech Co., Ltd.

Dong-Ha Shin

Kwang-Hee Son

Ho-Yong Park

Hyun-Woo Oh

Doo-Sang Park

Han-Young Cho

Kyu-Shik Jeong

Sang-Woon Shin

Mi-Gwang Kim

Do Young Kim

Myung-Sook Choi

Ho Yong Park

Tae Sook Jeong

Hyeon-Seon Ji

Hua Li

A composition for prevention or treatment of metabolic syndrome or for antioxidation includes black soybean leaf extracts and flavonol glycoside compounds isolated thereof as active ingredients. It has been confirmed that the black soybean leaf extracts and the flavonol glycoside compounds isolated thereof effectively inhibit &#x3b1;-glucosidase activity; LDL oxidation and DDP-4; have excellent DPPH radical scavenging activity; inhibitory activity of reactive oxygen species (ROS) accumulation; effectively promote insulin secretion; regulate the expression of major genes; have an excellent ability to reduce a waist/hip circumference ratio; decrease the concentrations of plasma free fatty acid and plasma triglyceride; increase the concentration of plasma HDL-cholesterol; decrease an atherogenic index; increase erythrocyte catalase, SOD and GR activities; decrease erythrocyte lipid peroxide TBARS; decrease the concentrations of inflammatory cytokines MCP-1 and PAI-1, and resistin; and increase the concentration of plasma adiponectin.

Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients

The present invention relates to a mannanase produced fromsp. strain HY-13 and more particularly to a highly active novel mannanase produced fromsp. strain HY-13 as separated from an invertebrate. The mannanase produced from the saidsp. strain HY-13 can be used in the decomposition of a mannan found in hemicellulose contained in grains and plants and in enhancing the utility value of a hydrolysate, which uses the decomposed mannan, for the transformation of biomass or as an animal feed material.

[object Object]

The invention provides a method for treating lung cancer or breast cancer wherein the method comprises administering a pharmaceutically effective dose of arazyme enzyme to a subject with lung cancer or breast cancer. The arazyme enzyme is either a protein comprising the amino acid sequence of SEQ ID NO: 1; and/or a protein encoded by DNA comprising the coding region of the nucleotide sequence of SEQ ID NO: 2.

Composition containing arazyme for the prevention and treatment of cancer

The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.

Pharmaceutical composition containing arazyme for the prevention of liver dysfunction

The present invention relates to a protease, and more specifically to a protease derived from, a gene coding for said enzyme, a gene expression system for said protease, a process for purifying the protease, and the uses of said protease in industrial applications, such as for example, detergents, cosmetics, leather processing agents, chemicals for laboratory research, solubilizing or softening agents for food, meat modifier, feed or food additives, or oil and fat separating agents, as well as pharmaceutical compositions.

Protease, a gene therefor and the use thereof

Growing community of inventors

Daejeon, South Korea

Dong-Ha Shin